SWA1211 / Beijing Stonewise Technology - LARVOL DELTA

SWA1211, a next generation HPK1 inhibitor exhibits superior anti tumor efficacy in preclinical studies (AACR 2025) - "We believe SWA1211 to be a promising next generation immune therapy for cancer patients.We have completed all IND enabling studies for SWA1211 and the results demonstrated a favorable drug-like profile. We expect to receive the green light for a clinical trial from the FDA and NMPA by March 2025; the clinical trial will be initiated immediately afterward."

Preclinical • Oncology

A Phase I First-in-Human Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of SWA1211 Tablets in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Beijing StoneWise Technology Co., Ltd

First-in-human • New P1 trial • Oncology • Solid Tumor